Results of immunohistochemical studies from several groups reveal diverse MTDH expressions in HER2 positive breast cancer tissues (ranging from 39% to 65%), emphasizing the potential role of MTDH in tumor progression [23, 27, 29, 34]. Here, ERBB2 is linked to breast carcinoma.